BioScrip (NASDAQ:BIOS) Stock Price Up 7.3%
BioScrip Inc (NASDAQ:BIOS)’s stock price shot up 7.3% during mid-day trading on Wednesday . The company traded as high as $3.12 and last traded at $3.07, 2,283,400 shares traded hands during trading. An increase of 104% from the average session volume of 1,119,774 shares. The stock had previously closed at $2.86.
BIOS has been the topic of several research reports. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Monday, November 11th. Zacks Investment Research cut shares of BioScrip from a “hold” rating to a “sell” rating and set a $4.00 price objective for the company. in a report on Monday, November 18th. SunTrust Banks upped their target price on shares of BioScrip from $3.25 to $4.25 and gave the stock a “buy” rating in a research note on Friday, September 20th. Canaccord Genuity upped their target price on shares of BioScrip from $3.50 to $4.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Finally, BidaskClub lowered shares of BioScrip from a “hold” rating to a “sell” rating in a report on Thursday. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. BioScrip currently has an average rating of “Hold” and a consensus price target of $4.79.
The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -6.40 and a beta of 0.44. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.36 and a current ratio of 1.71. The company has a 50 day moving average of $3.41 and a 200 day moving average of $2.99.
About BioScrip (NASDAQ:BIOS)
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.